Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from the Phase III APHINITY...

This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment landscape. Topics covered include; Roche...

This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; Anthera Pharmaceuticals announcing that it has commenced...

Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on; the results of the Phase III LATITUDE and STAMPEDE trials investigating...

This update bulletin presents key opinion leader (KOL) insights on recent events in the ovarian cancer treatment landscape. Topics covered include; the US approval and launch of Tesaro's PARP inhibitor Zejula (niraparib)...

This edition presents key opinion leader (KOL) views on recent developments in the treatment of rheumatoid arthritis (RA). Topics covered include; KOL views on the Food and Drug Administration’s issuance of a...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation of real-world...

This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent positive opinion from the European Medicines Agency (EMA) for Regeneron/Sanofi’s Kevzara...